Answers are grounded in this paper and cite their sources.
BACKGROUND: To evaluate the lifetime cost-effectiveness of once-daily umeclidinium/vilanterol (UMEC/VI) versus twice-daily aclidinium monotherapy for symptomatic chronic obstructive pulmonary disease (COPD) in Colombia. RESEARCH DESIGN AND METHODS: A lifetime Markov model with monthly cycles simulated moderate-to-very-severe COPD in a cohort aged 65 years, incorporating age- and severity-specific background mortality and a 12% case-fatality probability after each severe exacerbation. Comparative efficacy came from a published network meta-analysis; comparator exacerbation probabilities were derived on the rate scale. Costs and quality-adjusted life-years (QALYs) were discounted at 5% annually. Deterministic, scenario, and probabilistic sensitivity analyses were performed. RESULTS: UMEC/VI yielded 8.108 QALYs at US$24,956 per patient versus 6.312 QALYs and US$29,994 for aclidinium (incremental 1.796 QALYs; US$5,038 saved), making UMEC/VI dominant (net monetary benefit US$14,341). UMEC/VI was dominant in 94.7% and cost-effective in 98.6% of probabilistic simulations. Without its exacerbation benefit, UMEC/VI was not cost-effective (net monetary benefit -US$859). CONCLUSIONS: UMEC/VI is a high-value COPD maintenance therapy in Colombia, driven by exacerbation reduction rather than drug pricing and conditional on persistence of its clinical benefit.
No takes yet. Share an insight, caveat, or question.
Jefferson Antonio Buendía (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: